{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5c254927edaa95cf2906e186/5c635c7342c396c550c6dd50?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5c254927edaa95cf2906e186/1550077548031-b9504c2eb3a87d2f4f0d4b323c2f9a7b.jpeg?height=200","description":"<p><strong>CytoDyn Inc. (OTC: CYDY) CEO Interview with&nbsp;Nader Pourhassan, Ph.D, discussing CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer.</strong></p><p><br></p><p><strong>The company is at a key inflection point, with potential FDA approval for PRO140 for treating HIV expected in 2019.&nbsp;</strong></p><p><strong>Dr. Pourhassan explains the PRO140&nbsp;technology, its&nbsp;numerous advantages over current HIV therapies on the market, market potential, as well as expanding PRO140’s indications for treating cancer.&nbsp;</strong></p>","author_name":"WallStreetReporter.com"}